Beverly Paperiello
Abbott
10
0
9
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Hamid Gourabi, PhD
head of Royan Institute
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Mustafa H Temel, M.D.
Uskudar State Hospital
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Hillary Overholser
Zimmer Biomet
Shared therapeutic areas:
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
Shared therapeutic areas:
Alan Kivitz, MD
Altoona Center for Clinical Research
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
All 10 trials loaded